We are live on ! Find out more
BHVN

Biohaven Pharmaceutical Holding Company Ltd.
BHVN

Delisted

BHVN was delisted on the 3rd of October, 2022.

Back to rankings

2 hedge funds and large institutions have $13.5M invested in Biohaven Pharmaceutical Holding Company Ltd. in 2025 Q3 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

6% more capital invested

Capital invested by funds: $12.7M → $13.5M (+$808K)

0% more funds holding

Funds holding: 2 → 2 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.03%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
KCM
1
Knoll Capital Management
Florida
$13.4M – – –
FIA
2
FNY Investment Advisers
New York
$34K – – –

BHVN Hedge Fund Activity: Q3 2025 in Review

2 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q3 2025, worth a combined $13.5M — up 6.4% from $12.7M a quarter earlier.

Fund positioning in BHVN was balanced in Q3 2025: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 2 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q3 2025, unchanged from Q2 2025.
  • Funds reported $13.5M of Biohaven Pharmaceutical Holding Company Ltd. stock for Q3 2025, up 6.4% quarter-over-quarter.
  • 0 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q3 2025 and 0 closed out.

Based on aggregated 13F filings for Q3 2025.